Why is "Exenatide" trending?

Search Interest Perspective

• GCP Breakdown at King’s College Hospital Just Clouded the Most Promising Parkinson’s Trial in Years - The Clinical Trial Vanguard
• Novel plant-based approach to a better, cheaper GLP-1 delivery system - Penn Today
• Exenatide Alters Motor Network Activity in Parkinson Disease, Though Clinical Impact Remains Limited - NeurologyLive
• The Role of Exenatide, a Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist, in Idiopathic Intracranial Hypertension and Polycystic Ovary Syndrome: A Case Report - Cureus
• A case study on the analysis of exenatide using NMR spectroscopy - News-Medical
• History of GLP-1 Drugs: Complete Timeline From Exenatide (2005) to Tirzepatide and Beyond - PlexusDx
• A salute to innovation: exenatide in diabetes and obesity drug development at Amylin Pharmaceuticals - Nature
• After the recent exenatide results, what’s next in Parkinson’s disease research and clinical trials? - Van Andel Institute
• Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes - NEJM
• Shedding Light on Injection-site Reactions and Dermatological Risks of GLP-1RAs - The Dermatology Digest
• Medicine Supply Notification: Exenatide (Bydureon® BCise® ) 2mg/0.85ml prolonged-release suspension for injection pre-filled pen - Community Pharmacy England
• Low Doses of Ozempic-Like Drug Can Counteract Aging in Older Mice, Study Finds - Futurism
• Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial - The Lancet
• Amylin and Lilly Announce FDA Approval of BYETTA(TM) (Exenatide) Injection - Eli Lilly
• In 1992, Dr John Eng discovered a molecule in Gila monster venom; decades later, his finding helped pave - timesofindia.indiatimes.com
• Beyond Neurodegeneration: GLP-1 Receptor Agonists Find Their Footing in Stroke, Sleep, and Intracranial Pressure Disorders - NeurologyLive
• Exenatide and glucagon co-infusion increases myocardial glucose uptake and improves markers of diastolic dysfunction in adults with type 2 diabetes - Nature
• Exenatide and Rare Adverse Events - NEJM
• Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial - The Lancet
• The metabolic effects of adding exenatide to basal insulin therapy when targeting remission in early type 2 diabetes in a randomized clinical trial - Nature
• Effect of glucagon like peptide-1 receptor agonist exenatide, used as an intracranial pressure lowering agent, on cognition in Idiopathic Intracranial Hypertension | Eye - Nature
• GLP-1RAs Could Help People Quit Smoking - EMJ
• Effect of exenatide after short-time intensive insulin therapy on glycaemic remission maintenance in type 2 diabetes patients: a randomized controlled trial - Nature
• Bydureon BCise (exenatide prolonged-release) approved in the EU for paediatric patients with type-2 diabetes - AstraZeneca
• Pharmacokinetics of Exenatide in nonhuman primates following its administration in the form of sustained-release PT320 and Bydureon - Nature
• Invex Therapeutics (ASX: IXC): Can Exenatide’s Alzheimer’s Research Open a New Neurology Pathway? - kalkine.com.au
• Exenatide-PD3 results published - Cure Parkinson's
• Effects of Once-Weekly Exenatide on Clinical Outcomes in Patients With Preexisting Cardiovascular Disease: - American Heart Association Journals
• Dapagliflozin plus exenatide on patients with type 2 diabetes awaiting bariatric surgery in the DEXBASU study - Nature
• Making the diabetes drug exenatide more stable - C&EN
• The Bydureon (exenatide) phase 3 trial - Cure Parkinson's
• Gila monster: meet the lizard whose venomous bite is saving lives - Natural History Museum
• Once-Weekly Exenatide Treatment Does Not Increase Risk for Medullary Thyroid Carcinoma - Cancer Therapy Advisor
• PEGylated exenatide injection (PB-119) improves beta-cell function and insulin resistance in treatment-naïve type 2 diabetes mellitus patients - Frontiers
• FDA Approves Exenatide for Children and Teens with Type 2 Diabetes - Making Sense of Diabetes
• The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP–PKA–EGFR–STAT3 axis - Nature
• Effect of the GLP-1 receptor agonist exenatide on pro-inflammatory and metabolic biomarkers in individuals with alcohol use disorder: Post hoc results from a randomized, double-blinded, placebo-controlled clinical trial - Wiley Online Library
• BYETTA(R) (exenatide) Approved for Treatment of Type 2 Diabetes by European Commission - Eli Lilly
• Jury still out on effect of GLP-1 drugs on the eyes | AAO 2025 - Managed Healthcare Executive
• University of Birmingham reports new Phase II trial of exenatide for IIH - Clinical Trials Arena
• Effects of Exenatide With Pioglitazone or Insulin Therapy on Diabetic Neuropathy Measures - Endocrinology Advisor
• Why Did a GLP-1 Receptor Agonist Fail This Parkinson's Trial? - MedPage Today
• Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study - The Lancet
• Efficacy of the Glucagon-Like Peptide-1 Agonist Exenatide in Patients Undergoing CABG or Aortic Valve Replacement: A Randomized Double-Blind Clinical Trial | Circulation: Cardiovascular Interventions - American Heart Association Journals
• Exenatide, for diabetes, fails to slow motor decline in Phase 3 trial - Parkinson's News Today
• FDA approves once-weekly exenatide for children with type 2 diabetes - Healio
• Exenatide: A Potential Disease-Modifying Agent in PD? - NeurologyLive
• GLORIOUS: Neither Exenatide Nor Restrictive Oxygenation Boost CV Surgery Outcomes - TCTMD.com
• Study to Analyze New Glycemic Control Mechanism Emerges with Dapagliflozin/Exenatide Therapy in T2D - Physician's Weekly
• Pharmacokinetic/pharmacodynamic studies on exenatide in diabetic rats - Nature
• AstraZeneca announces new tolerability, long-term efficacy and real-world adherence data for exenatide once weekly in patients with type 2 diabetes - AstraZeneca
• Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) - The Lancet
• Exenatide - Nature
• The Changes of Lipidomic Profiles Reveal Therapeutic Effects of Exenatide in Patients With Type 2 Diabetes - Frontiers
• Targeted in vivo gene integration of a secretion-enabled GLP-1 receptor agonist reverses diet-induced non-genetic obesity and pre-diabetes | Communications Medicine - Nature
• Evaluation of NAFLD fibrosis, FIB-4 and APRI score in diabetic patients receiving exenatide treatment for non-alcoholic fatty liver disease - Nature
• Amneal Launches GLP-1 Agonist Exenatide Injection - Specialty Pharmacy Continuum
• FGF21 contributes to metabolic improvements elicited by combination therapy with exenatide and pioglitazone in patients with type 2 diabetes - American Physiological Society Journal
• No Difference Seen in Risk of Sight-threatening DR Among GLP-1 Drugs - Review of Optometry
• Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial - The Lancet
• Vivani's exenatide implant stimulates weight loss as well as Wegovy in mice - Fierce Biotech
• Safety & Efficacy of New Long-Acting Exenatide: Bydureon BCise - Diabetes In Control
• Real-World Data Show Advantages in People Treated with Lilly's Once-Weekly Trulicity® (dulaglutide) Compared to Those Treated with Liraglutide and Exenatide QW - PR Newswire
• Exenatide Reduces Risk of MACE for Type 2 Diabetes Patients - Diabetes In Control
• Antiobesity action of peripheral exenatide (exendin-4) in rodents: effects on food intake, body weight, metabolic status and side-effect measures - Nature
• Semaglutide vs Sitagliptin and Exenatide - Diabetes In Control
• Once-weekly Trulicity® (dulaglutide) demonstrates significantly higher adherence and more persistence compared to once-weekly semaglutide and exenatide injections - PR Newswire
• AstraZeneca’s exenatide once-weekly suspension for autoinjection - AstraZeneca
• GLP-1 drug shows little benefit for people with Parkinson's disease, trial finds - medicalxpress.com
• Promising results from study of type 2 diabetes drug in treatment of Parkinson’s disease - Van Andel Institute
• Exenatide treatment improves depression symptoms in PD patients - News-Medical
• Byetta (exenatide): Side Effects, FDA Warnings & Safety Information - Drugwatch.com
• IIH headaches could be treated with exenatide - PharmaTimes
• Battle of the GLP-1 Agonists: Liraglutide vs. Exenatide - Diabetes In Control
• AstraZeneca’s diabetes drug fails to slow Parkinson’s progression in UCL trial - Clinical Trials Arena
• Surface Adsorption-Mediated Ultrahigh Efficient Peptide Encapsulation with a Precise Ratiometric Control for Type 1 and 2 Diabetic Therapy - Wiley Online Library
• Update: New Study Finds Drugs like Ozempic Ineffective for Parkinson’s Treatment - parkinson.org
• Exenatide, a GLP-1 analog, by IV during cardiac surgery did not reduce organ injury or death - www.heart.org
• A Comparison of Safety & Efficacy of Semaglutide vs. Exenatide ER - Diabetes In Control
• Exenatide pre-filled pens discontinued with supplies exhausted - thepharmacist.co.uk
• The First Trial to Test GLP-1 Agonists in Adolescents - Making Sense of Diabetes
• Promising Results Reported for Once Monthly GLP-1 Agonist; Bydureon Inches Closer to Possible Approval - Making Sense of Diabetes
• The Phase 3 Exenatide results - Cure Parkinson's
• Third Time's a Charm for GLP-1 Diabetes Device? FDA Staff Suggest Otherwise. - MedPage Today
• Despite Early Promise GLP-1 Disappoints in Parkinson’s Disease - medscape.com
• Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial - The Lancet
• Diabetes Drug Exenatide Shows Promise against Parkinson’s Disease - Sci.News
• Repurposing a diabetes drug to crack Parkinson’s - Fierce Biotech
• FDA approves BYDUREON BCise for treatment of type 2 diabetes - Contemporary Pediatrics
• Bydureon EXSCEL trial meets primary safety objective in type-2 diabetes patients at wide range of cardiovascular risk - AstraZeneca
• US FDA approves Bydureon® Pen (exenatide extended-release for injectable suspension) - AstraZeneca
• Bydureon EXSCEL trial demonstrates favourable cardiovascular (CV) safety profile and fewer CV events in patients with type-2 diabetes at wide range of CV risk - AstraZeneca
• Exenatide - Springer Nature Link
• Lessons Learned From Vivani Medical's Study Of GLP-1 Implant - Clinical Leader
• Amylin Pharmaceuticals Files Suit Against Eli Lilly - Fierce Pharma
• A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study | Nauck | Clinical Diabetology - Via Medica Journals
• An exercise in expectations: Exenatide III - Cure Parkinson's
• Gene Editing Unlocks DIY Weight-Loss Drug Delivery - Technology Networks
• FDA panel votes against Intarcia’s GLP-1 implant - pharmaphorum
• US FDA approves new easy-to-use, once-weekly Bydureon BCise injectable medicine for patients with type-2 diabetes - AstraZeneca